Abstracts tagged "Systemic lupus erythematosus (SLE)"

Abstract Number: 0325 • ACR Convergence 2023
Understanding the Burden of Cutaneous Lupus: A Subset Analysis from the 2022 World Lupus Federation Global Impact (WLFGI) Patient Survey
Nnenna Ezeh¹, Joy Buie², Mike Donnelly³, Daria McClamb³, Lydia Oberholtzer⁴, Jana Sharp⁴ and Joseph Merola⁵, ¹Department of Dermatology; Department of Medicine, Harvard Medical School, Brigham and Women’s Hospital, Boston, MA, ²Lupus Foundation of America, York, SC, ³Lupus Foundation of America, Washington, DC, ⁴Sharp Insight, LLC, Montgomery County, MD, ⁵Harvard Medical School, Brigham and Women's Hospital, Newton, MA
Background/Purpose: There is a paucity of data among a global population exploring the burden of CLE on patients, especially as compared to patients with SLE.…
Abstract Number: 0551 • ACR Convergence 2023
Monogenic Lupus: Clinical Phenotypes and Genetic Mutations in a Cohort of Pediatric Patients
Keerthi Vardhan Yerram¹, Kavitha Shanigaaram¹, Gaurang Sudhir Deshpande¹, Akshay Parikh¹, Arjun Ramavath¹, Nanditha Gollakota¹, Ramesh Manthri¹ and Liza Rajasekhar², ¹Department of Clinical Immunology and Rheumatology, Nizams Institute of Medical Sciences, Hyderabad, India, ²Nizam's Institute of Medical Sciences, Madhapur, India
Background/Purpose: Monogenic lupus is associated with specific gene mutations, most commonly reported in TREX1, DNASE1L3, DNASE2, and SAMHD1. However, their phenotypes are not well reported.…
Abstract Number: 0569 • ACR Convergence 2023
Serum S100A8 and S100A9 Are Useful Biomarker Indicated IFN Associated Organ Involvements in Systemic Lupus Erythematosus
Risa Wakiya¹, Hiromi Shimada¹, Shusaku Nakashima¹, Taichi Miyagi², Yusuke Ushio³, Koichi Sugihara⁴, Mao Mizusaki¹, Rina Mino⁵, Kanako Chujo⁶, Ryoko Kagawa³, Hayamasa Yamaguchi³, Tomohiro Kameda¹ and Hiroaki Dobashi¹, ¹Division of Hematology, Rheumatology and Respiratory Medicine, Department of Internal Medicine, Faculty of Medicine, Kagawa University, Kagawa, Japan, ²Division of Hematology, Rheumatology and Respiratory Medicine, Department of Internal Medicine, Faculty of Medicine, Kagawa University, Kidagun, Japan, ³Division of Hematology, Rheumatology and Respiratory Medicine, Department of Internal Medicine, Faculty of Medicine, Kagawa University, Miki-cho, Kita-gun, Japan, ⁴Kagawa University, Miki-cho, Kita-gun, Japan, ⁵Kagawa University, Division of Hematology, Rheumatology and Respiratory Medicine, Department of Internal Medicine, Faculty of Medicine, Kagawa, Japan, ⁶Kagawa University, Miki, Kita District, Kagawa, Japan
Background/Purpose: S100, a damage-related molecular pattern factor, was reported to be a biomarker associated with disease activity in SLE. Additional hydroxychloroquine, which could regulate IFN…
Abstract Number: 0587 • ACR Convergence 2023
Impact of up to 24 Months Intravenous (IV) Belimumab (BEL) Treatment on Steroid Use and Disease Activity in Patients with SLE in Clinical Practice: Additional Post Hoc Pooled Analysis of Multicountry OBSErve Cohort Data
Daniel Moldaver¹, Seth Anderson², Marguerite Bracher³, Roger A. Levy⁴, Holly A. Quasny⁵, Robert Wood⁶, Rosie Wild⁶, Alexandra Cusmano⁶ and Elke Rottier⁶, ¹GlaxoSmithKline, Value Evidence and Outcomes, Ontario, Canada, ²GlaxoSmithKline, Value Evidence and Outcomes, Collegeville, PA, ³GlaxoSmithKline, Value Evidence and Outcomes, Stevenage, United Kingdom, ⁴GlaxoSmithKline, Global Medical Affairs, Collegeville, PA, ⁵GlaxoSmithKline, Research & Development, Durham, NC, ⁶Adelphi Real World, Real-World Evidence, Cheshire, United Kingdom
Background/Purpose: The clinical effectiveness of 6-month IV BEL use in SLE has previously been described in a post hoc pooled analysis from six OBSErve cohort…
Abstract Number: 0606 • ACR Convergence 2023
Risk of Damage Progression with Belimumab versus Oral Immunosuppressant Use in Patients with Systemic Lupus Erythematosus
April Jorge¹, Baijun Zhou¹, Yuqing Zhang² and Hyon K. Choi³, ¹Massachusetts General Hospital, Boston, MA, ²Division of Rheumatology, Allergy, and Immunology, Department of Medicine, Massachusetts General Hospital, Boston, MA, ³Massachusetts General Hospital and Harvard Medical School, Lexington, MA
Background/Purpose: Belimumab was approved for the treatment of non-renal SLE in 2011 and has been previously associated with a lower risk of damage progression when…
Abstract Number: 0827 • ACR Convergence 2023
Development and Initial Validation of a Brief Measure of Uncertainty in Rheumatic Disease
Caleb Bolden¹, Claire Cook¹, Lucy Finkelstein-Fox¹, Xiaoqing Fu¹, Flavia Castelino¹, Hyon K. Choi², Cory Perugino¹, John Stone³, Elyse Park¹, Zachary Wallace⁴ and Daniel Hall¹, ¹Massachusetts General Hospital, Boston, MA, ²Massachusetts General Hospital and Harvard Medical School, Lexington, MA, ³Massachusetts General Hospital Rheumatology Unit, Harvard Medical School, Concord, MA, ⁴Massachusetts General Hospital, Newton, MA
Background/Purpose: Patients with systemic autoimmune rheumatic disease (SARD) are often tasked with monitoring ambiguous and unpredictable physical symptoms on their own. Higher levels of uncertainty…
Abstract Number: 0900 • ACR Convergence 2023
Complement Deposition on Extracellular Mitochondria Induces Platelet Activation in Vitro
Marina Barguil Macedo and Christian Lood, University of Washington, Seattle, WA
Background/Purpose: Mitochondria are extruded upon cell death and platelet activation, being elevated in several inflammatory conditions, including systemic lupus erythematosus (SLE). Mitochondria are immunogenic, with…
Abstract Number: 0917 • ACR Convergence 2023
Role of Immunoglobulin Polygenic Risk in Systemic Lupus Erythematosus
Victor Gothefors-Holm¹, Sarah Reid¹, Ahmed Sayadi¹, Maija-Leena Eloranta¹, Martina Frodlund², Karoline Lerang³, Andreas Jonsen⁴, Solbritt Rantapää-Dahlqvist⁵, Anders Bengtsson⁴, Anna Rudin⁶, Oyvind Molberg³, Christopher Sjöwall², Johanna Sandling¹, Lars Rönnblom¹ and Dag Leonard¹, ¹Rheumatology, Department of Medical Sciences, Uppsala University, Uppsala, Sweden, ²Department of Biomedical and Clinical Sciences, Division of Inflammation and Infection/Rheumatology, Linköping University, Linköping, Sweden, ³Department of Rheumatology, Oslo University Hospital, Oslo, Norway, ⁴Rheumatology, Department of Clinical Sciences, Lund University, Lund, Sweden, ⁵Department of Public Health and Clinical Medicine/Rheumatology, Umeå University, Umeå, Sweden, ⁶Department of Rheumatology and Inflammation Research, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden
Background/Purpose: Systemic lupus erythematosus (SLE) is a chronic systemic autoimmune disease partly characterized by production of autoantibodies, causing inflammation and tissue damage. In this study…
Abstract Number: 1062 • ACR Convergence 2023
Antiretinal Autoantibodies in Hydroxychloroquine Eye Toxicity
Samuel Good¹, Grazyna Adamus², Michael Gorin³, Jordan Jacquez¹, Jennifer Grossman¹, Brian Skaggs¹, Ashira Hasan² and Maureen McMahon⁴, ¹University of California Los Angeles, Los Angeles, CA, ²Oregon Health & Science University, Portland, OR, ³Jules Stein Eye Institute, University of California Los Angeles, Los Angeles, CA, ⁴UCLA David Geffen School of Medicine, Los Angeles, CA
Background/Purpose: Autoimmune retinopathy (AIR) is a disease process in which circulating autoantibodies (AAbs) against retina-specific antigens cause local inflammation and can lead to blindness. Hydroxychloroquine…
Abstract Number: 1241 • ACR Convergence 2023
Adverse Childhood Experiences in a Paediatric Systemic Lupus Erythematosus Cohort
Stephanie Fevrier¹, Olivia Hendrikx¹, Ashley Danguecan¹, Asha Jeyanathan¹, Lawrence Ng¹, Ibrahim Mohamed², Paris Moaf¹, Sondos Ayyash¹, Chelsea DeCoste³, Deborah Levy¹, Linda Hiraki¹ and Andrea Knight¹, ¹The Hospital for Sick Children, Toronto, ON, Canada, ²The Hospital for Sick Children, Brampton, ON, Canada, ³IWK Health Centre, Halifax, NS, Canada
Background/Purpose: Systemic lupus erythematosus (SLE) is a chronic, multiorgan autoimmune disease in which 20% of cases are diagnosed in childhood. Adverse childhood experiences (ACEs) are…
Abstract Number: 1443 • ACR Convergence 2023
Vasculitis Associations Among Patients with Systemic Lupus Erythematous
Emily Cosentino¹, Mia Blanchard², Diane L. Kamen¹ and Jim Oates¹, ¹Medical University of South Carolina, Charleston, SC, ²Claremont Graduate University, Claremont, CA
Background/Purpose: Vasculitis is rare manifestation of systemic lupus erythematous (SLE) that often leads to increased morbidity and mortality. Vasculitis prevalence in SLE patients have ranged…
Abstract Number: 1460 • ACR Convergence 2023
Impact of Neuropsychiatric Involvement on Health-related Quality of Life in Patients with Systemic Lupus Erythematosus
Dionysis Nikolopoulos¹, Nursen Cetrez², Julius Lindblom² and Ioannis Parodis², ¹Karolinska Institutet and Karolinska University Hospital, Division of Rheumatology, Department of Medicine Solna, Stockholm, Sweden, ²Karolinska Institutet, Stockholm, Sweden
Background/Purpose: Substantial proportions of systemic lupus erythematosus (SLE) patients report severe fatigue and adverse Health-related Quality of Life (HRQoL). Particularly neuropsychiatric manifestations have been associated…
Abstract Number: 1476 • ACR Convergence 2023
Discriminating Disease Flare from Infection in Febrile Patients with Systemic Lupus Erythematosus Admitted to a Safety-Net Hospital System: A Retrospective, Multicenter Study
Abhimanyu Amarnani¹, Flora Liu², Melissa Lee Wilson², Nathan Lim², William Stohl³ and Leanna Wise⁴, ¹NYU Langone Medical Center, New York, NY, ²Keck School of Medicine and LAC+USC Medical Center, Los Angeles, CA, ³University of Southern California Keck School of Medicine, Division of Rheumatology, Los Angeles, CA, ⁴LAC+USC/Keck Medicine of USC, Pasadena, CA
Background/Purpose: Fever in systemic lupus erythematosus (SLE) patients presents a diagnostic challenge as the differential diagnosis includes disease flare and infection. Identifying laboratory parameters to…
Abstract Number: 1494 • ACR Convergence 2023
The Effect of Belimumab on Steroid Use in Patients with SLE: Results from a Retrospective Observational Study of Real-World Data from a US Rheumatology Provider Network
Karen Worley¹, Scott Milligan² and Bernard Rubin³, ¹GlaxoSmithKline, US Value Evidence and Outcomes, Cincinnati, OH, ²Trio Health, Analytics, Louisville, CO, ³GlaxoSmithKline, US Medical Affairs and Immuno-inflammation, Durham, NC
Background/Purpose: While oral CS (OCS) are the mainstay of SLE therapy, prolonged use is associated with organ damage and early mortality.1,2 Minimizing OCS use is…
Abstract Number: 1522 • ACR Convergence 2023
Treatment of Pulmonary Arterial Hypertension in Patients with Connective Tissue Diseases: A Meta-analysis
Mustafa Erdogan¹, Sinem Nihal Esatoglu², Burcak Kilickiran Avci³ and Gulen Hatemi², ¹Marmara University - Pendik Training and Research Hospital, Department of Internal Medicine, Division of Rheumatology, Istanbul, Turkey, ²Istanbul University-Cerrahpasa, Cerrahpasa Medical School, Department of Internal Medicine, Division of Rheumatology, Istanbul, Turkey, ³Istanbul University-Cerrahpasa, Cerrahpasa Medical School, Department of Cardiology, Istanbul, Turkey
Background/Purpose: Treatment options for pulmonary arterial hypertension (PAH) have expanded in the last two decades. However, evidence for the treatment of connective tissue disease-associated PAH…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].